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Sound evidence indicates that microRNAs (miRNAs) are aberrantly expressed in 
Alzheimer’s disease (AD) patients. We performed a systematic review and meta-analysis 
to investigate the role of miRNA in AD pathogenesis and their clinical diagnostic value; a 
systematic review of literature and meta-analysis of clinical trials were performed. In the 
systematic review, 236 papers were included, and we reviewed the dysregulated miRNA 
expression in different parts of AD patients in order to identify the relationship between 
aberrantly expressed miRNAs and AD pathology. In the subsequent meta-analysis, 
seven studies were statistically analyzed with the following results: pooled sensitivity 
0.86 (95%CI 0.79–0.90), pooled specificity 0.87 (95%CI 0.72–0.95), diagnostic odds 
ratio (28.29), and the area under the curve (0.87). In conclusion, our review indicated 
that aberrant expression of various miRNAs plays an important role in the pathological 
process of AD, and statistical analysis of quantitative studies reveal the potential value of 
specific miRNAs in the diagnosis of AD.
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iNTRODUCTiON
Alzheimer’s disease (AD) is the most common form of dementia among the aging population, char-
acterized pathologically by the progressive accumulation of extracellular amyloid-beta (Aβ) plaques 
and intracellular neurofibrillary tangles (NFT) (Goedert and Spillantini, 2006). The insidious nature 
of its onset may delay the diagnosis of AD for several years, and late diagnosis leads to poor patient 
prognosis. Currently, diagnostic approaches to AD involve clinical findings, neuropsychological test-
ing, and neuroimaging assessment, but there lacks a method that has high sensitivity and specificity, 
especially for early diagnosis (Huang and Mucke, 2012). Even though many studies suggest that Aβ 
imaging using positron emission tomography (PET) scanning and Aβ levels measurement in CSF 
and serum may serve as promising methods in diagnosis, the high cost and invasive nature preclude 
their utility for routine clinical tests.
Recently, increasing evidence indicates that microRNA (miRNA) plays a major role in the 
brain, involving in neural development and differentiation (Jiang et al., 2013; Lin et al., 2014). 
microRNAs (miRNAs) are conserved small non-coding RNAs and modulate gene expression 
negatively at the post-transcriptional level. Approximately 70% of the currently identified 
 miRNAs are expressed in the brain (Lausted et al., 2014; Bennett et al., 2015). Therefore, miRNAs 
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may serve a potential role in monitoring neurodegenerative 
processes, and specific miRNAs may correlate with certain 
neurodegenerative diseases. They may act as biomarkers to 
discern and identify the neurodegenerative process in disor-
ders like AD before clinical symptoms and functional decline 
become apparent.
We conducted a systematic review of related qualitative and 
quantitative studies to collaborate the findings on changes of 
miRNA expression in different parts of the brains in patients with 
AD. We also evaluated the diagnostic value of miRNAs for AD 
through completing this meta-analysis.
MATeRiAL AND MeTHODS
Literature Search
We searched the following electronic bibliographic databases: 
MEDLINE, EMBASE, The Cochrane Library (Cochrane 
Database of Systematic Reviews), Cochrane Central Register of 
Controlled Trials (CENTRAL), Health Technology Assessment 
Database, and Web of Science (science and social science cita-
tion index). Furthermore, we searched the Chinese databases of 
China National Knowledge Infrastructure (CNKI), Wan Fang 
Data, Technology of Chongqing VIP database, and SinoMed for 
related studies. The search strategy included terms relating to or 
describing the clinical trials of diagnosis. The search terms are 
adapted for use with other bibliographic databases in combina-
tion with database-specific filters for controlled trials, where 
these are available. The language was restricted to English and 
Chinese and the publication date from January 1990 to June 2015. 
The search terms were “Alzheimer’s disease/AD/dementia of the 
Alzheimer’s type/Alzheimer dementia,” “microRNA/miRNA,” 
“diagnosis,” “sensitivity,” and “specificity.”
The protocol has been registered in PROSPERO, an interna-
tional prospective register of systematic review with a registration 
No. CRD42015015925.
inclusion and exclusion Criteria
In the systematic review, we included all quantitative and 
qualitative studies, reports, letters, reviews, editorial articles, or 
conference abstracts examining the relationship between miRNA 
expression and AD. Those literatures were included regardless of 
quality.
For meta-analysis, a study was included if it met all of the 
following criteria: (1) randomized trials or observational stud-
ies (including cohort and case-control studies); (2) all included 
patients were diagnosed with AD using clinically recognized 
diagnostic criteria; (3) clinical studies on evaluation of miRNAs 
in the diagnosis of AD; (4) inclusion of sufficient data on the size 
of samples and the sensitivity and specificity data. Publications 
with limited data information or overlap of patient selection with 
other included studies were excluded.
Data extraction and Quality Assessment 
of included Studies
In meta-analysis, the final included studies were independently 
assessed by two reviewers using a standardized form. Information 
retrieved from these articles included: the first author, publica-
tion year, sample size, specimen, miRNA expression signature, 
sensitivity, and specificity data. The methodological quality of 
included studies were assessed by QUADAS (quality assessment 
for studies of diagnostic accuracy), which is an evidence-based 
quality assessment tool for systematic reviews of diagnostic 
accuracy studies (Whiting et al., 2006, 2011; Mann et al., 2009).
Statistical Analysis of Meta-Analysis
The true positives (TP, the individual has the condition and tests 
positive for the condition), false positives (FP, the individual 
does not have the condition but tests positive for the condition), 
true negatives (TN, the individual does not have the condition 
and tests negative for the condition), and false negatives (FN, 
the individual has the condition but tests negative for the condi-
tion) were calculated with obtained data after constructing 2 × 2 
contingency tables. The following indices were computed: pooled 
sensitivity, pooled specificity, positive likelihood ratio (PLR), 
negative likelihood ratio (NLR), diagnostic odds ratio (DOR), 
and their corresponding 95% confidence intervals (CI). Fagan’s 
nomogram was used for post-test probability calculations. 
Cochran-Q value and I2 test were used to assess heterogeneity 
across studies. Deek’s funnel plots were adopted to investigate 
publication bias. All analyses were performed with the following 
software programs: Stata, review manager 5.3 and Meta-Disc 1.4. 
All statistical tests were two sided, and the significance level was 
set at p < 0.05.
ReSULTS
Systematic Review: identified Relationship 
between miRNA and AD
miRNA Dysregulation Found in Different Human 
Tissues/Samples (Table 1)
Peripheral Blood 
Peripheral blood sampling is a minimally invasive procedure that 
is simple and inexpensive to perform. The remarkable stability 
despite the abundance of endogenous RNAs in biofluid allows 
postulation of the pathogenesis in AD, as well as opening up an 
avenue for developing new diagnostic tests in clinical practice 
(Kiko et al., 2014). In 2007, Schipper and colleagues reported that 
expression of nine miRNAs was increased in the peripheral blood 
mononuclear cells of AD patients, and subsequently, Geekiyanage 
et al. (2012) discovered that miR-137, miR-181c, miR-9, and miR-
29 were downregulated in the serum of AD patients as well as 
AD mouse models. In patients with mild cognitive impairment 
(MCI), there appears to be an increased level of brain enriched 
miRNAs from the miR-132 and miR-134 families compared to age 
matched controls (Sheinerman and Umansky, 2013). Moreover, 
Tan et al. (2014b) applied high through sequencing to genome-
wide serum miRNAs and identified miR-342-3p as a potential 
serum biomarker in aiding the diagnosis of AD, with a sensitivity 
of 81.5% and specificity of 70.1%. These explorations suggested a 
promising role for serum miRNAs to serve as a diagnostic marker 
for AD, although further analysis and validation of these results 
would be required.
TABLe 1 | Systematic review: miRNA dysregulation in different parts.
Brain-based miRNA CSF-based miRNA Blood-based miRNA
Cortex Hippocampus Plasma Serum PBMC
miR-129-5p miR-132-3p miR-34a, miR-125b miR-34a/c miR-137 miR-34a
miR-27a-3p miR-128 miR-146a, miR-29a miR-146a miR-18c miR-181b
miR-92b-3p miR-136-5p miR-27a-3p miR-128 miR-9 miR-200a
miR-200a miR-138-5p miR-24, miR-126 miR-132 miR-29a let-7f
miR-148 miR-145 miR-10a/b, miR-16 miR-29a/b let-7f
miR-370 miR-124-3p miR-138, miR-141 miR-874 miR-29b
miR-409-5p miR-129-5p miR-143, miR-151 miR-134 miR-126
miR-127-5p miR-129-2-3p miR-181a/c miR-323-3p miR-34a
miR-496 miR-487 miR-191, miR-194 miR-382 miR-181b
miR-633 miR-370 miR-195, miR-204 miR-137
miR-874 miR-409-5p miR-205, miR-214 miR-181c
miR-487 miR-221, miR-338




Lau et al. (2013),  
Delay et al. (2012)
Bekris et al. (2013), Cogswell  
et al. (2008), Kiko et al. (2014),  
Muller et al. (2014), Sala Frigerio  
et al. (2013), Burgos et al. (2014)
Kumar et al. (2013), Bekris 
et al. (2013), Bhatnagar 
et al. (2014), Kiko et al. 
(2014)
Leidinger et al. (2013), 
Cheng et al. (2014), Tan et al. 




TABLe 2 | Systematic review: miRNA dysregulation linked to AD 
pathogenesis.
AD pathology miRNA Reference
APP miR-101, miR-17-5p,  
miR-106b, miR-107,  
miR-20a, miR-30,  
miR-143, miR-153,  
miR-193, miR-9, miR-16
Satoh (2012), Schonrock 
et al. (2010), Delay et al. 
(2011), Wang et al. (2008), 
Liu et al. (2012), Hebert et al. 
(2009), Chang et al. (2014)
BACE1 miR-29a/b, miR-9, miR-5a, 
miR-19b, miR-298, 
miR-285-5p, miR-486,  
miR-107, miR-195
Hebert et al. (2008), Long 
et al. (2014), Schonrock et al. 
(2010), Satoh (2012)
Tau miR-132,miR-125b,  
miR-26b,miR-128,  
miR-922, miR-34, miR-15, 
miR-512
Absalon et al. (2013), Dickson 
et al. (2013), Banzhaf-
Strathmann et al. (2014), 
Zhao et al. (2014), Dickson 
et al. (2013), Mezache et al. 
(2015)
PSEN1 miR-214, miR-153,  
miR-516a, miR-511,  
miR-128, miR-340, miR-335
Delay et al. (2012), Satoh 
(2012), Mallick and Ghosh 
(2011), Kalani et al. (2013)
Apoptosis let-7, miR-15a, miR-29,  
miR-17-5p, miR-26b,  
miR-21, miR-191, miR-590-
3p, miR-132, miR-212
Absalon et al. (2013), Tan 
et al. (2013), Wong et al. 
(2013), Villa et al. (2011)
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Cerebrospinal Fluid
Apart from blood-based analysis, miRNA from cerebrospinal 
fluid (CSF) has gained increasing attention in studies exploring for 
potential AD biomarkers, as Aβ, total tau, and phosphorylated tau 
levels in CSF can support the clinical diagnosis of AD with accept-
able sensitivity and specificity (Ghidoni et al., 2011; Blennow and 
Zetterberg, 2013; Lleo et al., 2015). Cogswell et al. (2008) exam-
ined post-mortem CSF and found 60 miRNAs expression levels 
were significantly different between AD patients and normal 
controls. However, in ante-mortem cell free CSF, most selected 
miRNAs were undetectable or only minimally detectable, pro-
ducing a highly variable result when compared to former reports 
(Muller et al., 2014). Nevertheless, in the same study, miR-146a 
was significantly decreased in CSF of AD patients and low level of 
146a was associated with disease progression (Muller et al., 2014).
Brain Tissues
Five hippocampal miRNAs (miR-370, miR-328, miR-15a, miR-
138, and miR-132) were identified with sound sensitivity and 
specificity in predicting AD plaques scores or Braak stages, sug-
gesting that expression levels of dysregulated miRNAs may con-
tribute to the AD neuronal pathology (Absalon et al., 2013; Bekris 
et al., 2013; Lau et al., 2013). The trend of miRNAs expression 
across the Braak stages is shown in Figure S1 in Supplementary 
Material. Moreover, variations in miRNAs expression in differ-
ent brain regions may represent specific patterns of pathology 
(Hebert et  al., 2010), which may be useful in characterizing 
specific miRNA biomarkers in AD diagnosis. Most existing stud-
ies examined miRNA in the hippocampus or cerebral cortex in 
the post-mortem setting and obtaining live tissue through biopsy 
would prove to be challenging.
miRNA Dysregulation involved in AD 
Pathogenic Protein or Process
Traditionally, we focused on the proteins changes related directly 
to pathogenesis for the onset and development of AD. Recently, 
however, a large-scale annotation of human genome provided 
evidence that miRNAs play an important role in the molecular 
pathogenesis of AD, both genetic and sporadic. miRNAs serve 
as important gene regulators and are critical for gene expression 
and demonstrated potential for novel therapeutic avenues in AD 
treatment (Berezin et al., 2014)
The single-stranded activated miRNAs can target comple-
mentary regions of message transcripts through base pairing 
mechanism, which results in either translational inhibition or 
degradation of mRNA (Wang, 2010). To date, several studies have 
demonstrated an altered expression of miRNAs in AD patients 
and how these alterations may play a direct role in moderating 
the expression of AD-related genes and subsequent phenotypic 
manifestation (Kiko et al., 2014). Even though a single miRNA 
TABLe 3 | Summary of included studies.




Specimen TP FP FN TN QUADAS miRNA profile
1 Leidinger et al. (2013) 48 22 Plasma 44 1 4 21 10 miR-112, 161, 5010-3p, 26a-5p, 1285-5p, 151-3p
2 Tan et al. (2014a) 158 155 Serum 127 49 31 106 13 miR-98-5p, 885-5p, 483-3p, 191-5p, let-7d-5p
3 Cheng et al. (2014) 15 35 Serum 13 8 2 27 10 miR-1306-5p, 342-3p, 15b-3p
4 Tan et al. (2014b) 105 150 Serum 85 48 20 102 12 miRNA-125b
5 Lau et al. (2013) 41 23 Hippocampus 37 0 4 23 13 miR-132-3p, 128, 136-5p, 138-5p, 124-3p, 129-5p
6 Muller et al. (2014) 20 30 CSF 12 2 8 18 13 miR-16
7 Kumar et al. (2013) 31 37 Plasma 29 2 2 35 11 miR-545-3p, let-7g-5p
Total 418 442
7 studies included for 
meta-analysis
78 full-text articles excluded: not 
satisfying the selection criteria, 
insufficient data, patient overlap.
236 records for narrative 
synthesis
151 records excluded: letters, 
reviews, editorial articles or non
clinical studies
207 records identified through 
database searching
29 additional records identified 
through other sources
236 records after duplicates removed
85 full-text articles 
assessed for eligibility
FiGURe 1 | Process of study selection.
TABLe 4 | Accuracy estimates of included studies.
Study Reference Sensitivity (95%Ci) Specificity (95%Ci) PLR (95%Ci) NLR (95%Ci) DOR (95%Ci)
1 Leidinger et al. (2013) 0.92 (0.80, 0.98) 0.95 (0.77, 1.00) 20.17 (2.96, 137.12) 0.087 (0.034, 0.224) 231.00 (24.29, 2196.30)
2 Tan et al. (2014a) 0.80 (0.73, 0.86) 0.68 (0.60, 0.76) 2.54 (1.99, 3.25) 0.287 (0.206, 0.400) 8.86 (5.28, 14.88)
3 Cheng et al. (2014) 0.87 (0.60, 0.98) 0.77 (0.60, 0.90) 3.79 (1.99, 7.19) 0.173 (0.047, 0.636) 21.94 (4.07, 118.28)
4 Tan et al. (2014b) 0.81 (0.72, 0.88) 0.68 (0.60, 0.75) 2.53 (1.97, 3.25) 0.280 (0.186, 0.422) 9.03 (4.98, 16.39)
5 Lau et al. (2013) 0.90 (0.77, 0.97) 1.00 (0.85, 1.00) 42.86 (2.75, 666.92) 0.109 (0.046, 0.262) 391.67 (20.16, 7610.80)
6 Muller et al. (2014) 0.60 (0.36, 0.81) 0.90 (0.68, 0.99) 6.00 (1.54, 23.44) 0.444 (0.255, 0.775) 13.50 (2.43, 74.87)
7 Kumar et al. (2013) 0.94 (0.79, 0.90) 0.95 (0.82, 0.99) 17.31 (4.48, 66.83) 0.068 (0.018, 0.261) 253.75 (33.63, 1914.40)
Total 0.86 (0.79, 0.90) 0.87 (0.72, 0.95) 4.29 (2.62, 7.03) 0.206 (0.133, 0.319) 28.29 (11.095, 72.16) 
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A large number of exploratory studies attempted to identify 
biologically and physiologically relevant molecular networks in 
AD by searching for meaningful changes in miRNA expression 
and potential surrogate diagnostic biomarkers in AD. AD-related 
proteins such as amyloid precursor protein (APP), beta-secretase 
can target hundreds of genes, the genes co-regulated by a set of 
miRNAs generally encode for a related network of functionally 
associated molecules. Hence, even small changes in the expression 
level of miRNAs could affect a wide range of signaling pathways 
involved in cellular physiological functions.
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1 (BACE1), presenilin-1 (PSEN1), and MAPT (tau) and neuronal 
apoptosis have been thoroughly investigated during this search 
(Table 2).
miRNA Differently expressed According 
to Gender and Apoe
It is believed that AD may be more prevalent in females than 
males (van Harten et  al., 2015). Given that many reports of 
miRNA dysregulation in AD patients, several groups of research-
ers’ studies have started exploring how gender affects miRNA 
expression. For example, in mice models of AD, Geekiyanage 
et  al. (2012) found the expression of miR-137, miR-181c, and 
miR-29 were decreased in the cortex of female mice compared 
to the males. Subsequently, they proved that these three miRNAs 
were also downregulated in serum of probable AD and amnestic 
MCI mice. APOE allele is also considered to be an important 
risk factor for AD, as the prevalence of APOE ϵ4 is significantly 
higher in the AD group. In 2014, Cheng et  al. identified four 
clusters of miRNA, which showed clear associations with APOE 
ϵ4 allele status. They further selected 16 miRNAs markers based 
on the contribution toward clinical classification of AD through 
random forest analysis. Furthermore, a model derived from the 
study incorporating selected miRNAs, age, gender, and APOE 
ϵ4 allele status had correctly diagnosed 13 out of 15 AD partici-
pants AD patients with high accuracy (87% sensitivity and 77% 
specificity)
MeTA-ANALYSiS: DiAGNOSTiC  
vALUe OF miRNA FOR AD
Data Characteristics and Quality 
Assessment
We identified seven English publications focusing on miRNAs 
expression for diagnosis of AD. The details of the selection pro-
cess were presented in Figure 1.
A total of 418 cases and 442 controls were involved for analysis 
across the seven studies and the data characteristics with the 
QUADAS score of each study were listed in Table 3. All patients 
with AD were diagnosed with clinically recognized diagnostic 
criteria.
The specimens used for miRNA analysis included CSF, hip-
pocampus, plasma, and serum. The miRNAs expressions were 
FiGURe 2 | Forrest plot of estimates of sensitivity and specificity.
February 2016 | Volume 8 | Article 136
Hu et al. microRNA for AD Diagnosis
Frontiers in Aging Neuroscience | www.frontiersin.org
patients being asymptomatic at the early stage (Iacono et  al., 
2008). Given that miRNAs plays a critical role in neural devel-
opment and neurological diseases, it is reasonable to assume 
that they may serve as putative markers of AD. The overall 
aim of this investigation was to evaluate the diagnostic value 
of miRNAs in AD and examine the correlation between AD 
associated neurodegeneration and the expression of miRNAs in 
CSF, hippocampus or serum, especially in the early subclinical 
stages of AD.
To date, the correlation of miRNA dysregulation with AD has 
been widely studied. However, the results of these studies had not 
always been consistent and no consensus has yet been reached. 
We are undoubtedly just at the beginning of exploring this field, 
and there remains an immense amount of work to fully define the 
relationship between miRNAs and AD. First, we have reviewed 
more than 50 miRNAs, which expressed aberrantly in biofluid 
and brain of AD. Most of miRNAs are downregulated; by con-
trast, some specific miRNAs are significantly upregulated, such 
as miR-29, miR-339, and miR-214. Then, we further explored 
the dysregulation of miRNAs in the pathological process of AD 
including APP metabolism, Tau pathology, neuroinflammation, 
FiGURe 3 | Summary receiver operating characteristic (SROC) curve. 
Observed data obtained from meta-analysis (Cheng et al., 2014; Kumar 
et al., 2013; Lau et al., 2013; Leidinger et al., 2013; Muller et al., 2014; Tan 
et al., 2014a,b).
FiGURe 4 | Fagan’s Nomogram for assessment of post-test 
probabilities. Observed data obtained from meta-analysis (Cheng et al., 
2014; Kumar et al., 2013; Lau et al., 2013; Leidinger et al., 2013; Muller 
et al., 2014; Tan et al., 2014a,b).
detected by quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) and in situ hybridization (ISH). After analyz-
ing each study, their QUADAS scores ranged from 10 to 13.
Heterogeneity Analysis and Diagnostic 
value of miRNAs
The heterogeneity I2 value for inter-study variability is 78.39%. 
As a result, the summary assessment of miRNAs in the 
diagnosis of AD showed that the pooled sensitivity was 0.86 
(95%CI: 0.79–0.90) and the pooled specificity was 0.87 (95%CI: 
0.7–0.95) (Table  4; Figure  2). The area under the summary 
receiver operating characteristic curve was 0.91 (Figure 3). The 
PLR was 7 and the NLR is 0.17, as demonstrated in the Fagan’s 
nomogram in Figure  4. Moreover, the combined diagnostic 
odds ratio was 28.29.
Furthermore, in order to decrease the mixing affects in 
interpreting the results, we performed another analysis using 
body fluid miRNAs, including plasma, serum, and CSF miRNAs 
in the diagnostic test of AD. This analysis shows similar results 
compared to the former comprehensive meta-analysis (Figures 
S2 and S3 in Supplementary Material).
Publication Bias
Funnel plots were used to assess the publication bias of the included 
studies in meta-analysis as listed in Figure 5. Furthermore, in a quan-
titative method, the Deek’s test was performed and the p was 0.07.
DiSCUSSiON
The development of sensitive and specific biomarkers for 
diagnosing AD remains a great challenge, especially with most 
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and apoptosis. Many studies suggest that miRNAs serve as critical 
regulators in those signaling pathways and the dysregulated miR-
NAs could influence gene transcription and protein expression 
and induce the spread of neurodegeneration (Faghihi et al., 2010; 
Schonrock and Gotz, 2012).
In meta-analysis, the quality of most studies was relatively 
good to a certain extent with QUADAS scores ranged from 10 
to 13 and the pooled sensitivity was 0.86 and specificity was 
0.87 with an AUC of 0.91. We also found that the DOR upon 
combining the pooled sensitivity and specificity was 28.29, which 
further supports miRNAs as a potential diagnostic tool for AD. 
For assessment of post-test probabilites, Fangan’s Nomogram was 
used, and its results indicated that the PLR was 7, suggesting a 
patient with AD is seven times more likely to have positive results 
than a normal person, which reveals that both likelihood ratios 
and post-test probabilities were moderate. In publication bias 
assessment, according to our selection criteria in meta-analysis, 
only clinical studies were included and some data such as reports, 
conference abstracts, and non-English and non-Chinese literature 
were excluded, which probably causes publication bias to some 
degree, but there is no significant evidence for publication bias 
in the Deek’s test.
However, several limitations complicate the interpretation 
of our meta-analysis. First, heterogeneity is a major problem in 
interpreting the results. miRNAs expression may vary between 
CSF, hippocampus, and peripheral blood, which may result in 
different diagnostic efficiency of miRNAs for AD. Additionally, 
the studies utilized different methods for quantitative detection 
and normalization in miRNA analysis, which may account for the 
differences reported across different studies. Finally, the relatively 
small sample size of each study as well as the limited number of 
eligible studies would also affect the statistical power of our results.
In conclusion, the present meta-analysis suggests a promising 
role of miRNAs in the detection of AD. Compared to other existing 
FiGURe 5 | Funnel graph for the assessment of publication bias. Observed studies obtained from meta-analysis (Cheng et al., 2014; Kumar et al., 2013;  
Lau et al., 2013; Leidinger et al., 2013; Muller et al., 2014; Tan et al., 2014a,b).
markers, the miRNA biomarkers has the advantage of being eas-
ily accessible and rapidly analyzed and could provide insight to 
the early diagnosis of AD, and recent studies are demonstrating 
improving sensitivity and specificity. However, currently, there 
still lacks a clear classification for tissue based or blood-based 
miRNAs. Future prospective, multi-centered, large-scale clinical 
trials will further aid the establishment of miRNA combinations 
as diagnostic biomarkers for AD. Moreover, further studies on 
to further elucidate the pathophysiological interaction between 
miRNAs and AD-related proteins are also required.
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